The ability of ETA/BRA (bosentan) to contrast these ET-1 effects might be important primarily in those fibrotic diseases characterized by high circulating levels of ET-1 and by the presence of macrophage infiltrate, as observed in SSc and type 2 diabetes [11,12]. Here, EDN1 is linked to systemic sclerosis.